Low-Dose Ketamine Modulates Brain Entropy in TRD: Neuroimaging Evidence

Low-Dose Ketamine Alters Brain Entropy in Treatment-Resistant Depression

Two recent clinical trials provide neuroimaging evidence that low-dose ketamine modulates brain entropy in patients with treatment-resistant depression (TRD), according to a peer-reviewed article published on October 26, 2026 (OpenAlex). Brain entropy, a measure of the complexity and unpredictability of neural activity, is increasingly recognized as a potential biomarker for psychiatric states and treatment response. The trials, which enrolled adults diagnosed with TRD, used advanced neuroimaging techniques to quantify changes in brain entropy before and after administration of subanesthetic ketamine doses.

Both studies reported statistically significant increases in brain entropy following ketamine infusion, correlating with reductions in depressive symptoms as measured by standardized clinical scales. While the trials did not directly assess long-term clinical outcomes, the findings suggest that acute changes in neural complexity may underlie ketamine's rapid-acting antidepressant effects. This mechanistic insight could inform the development of objective biomarkers for response to psychedelic and dissociative therapies.

Mechanistic Insights: Brain Entropy as a Biomarker

Neuroimaging data from these trials indicate that ketamine-induced increases in brain entropy are associated with clinical improvement in TRD. Brain entropy, often calculated from functional magnetic resonance imaging (fMRI) or electroencephalography (EEG) data, reflects the diversity and flexibility of neural network activity. In depressive states, brain entropy is typically reduced, indicating more rigid and predictable neural dynamics.

The observed post-ketamine entropy increase supports the hypothesis that restoring neural complexity may be a key mechanism of rapid antidepressant response. This aligns with previous research linking higher brain entropy to improved cognitive and emotional flexibility. Notably, the studies used both resting-state and task-based neuroimaging protocols, strengthening the generalizability of the findings across different brain states. One non-obvious implication is that entropy measures could help distinguish between pharmacological effects of ketamine and placebo responses, a challenge in psychedelic and dissociative drug trials due to pronounced subjective effects.

Implications for Clinical Development and Research Policy

These findings have several implications for the clinical development of ketamine and related compounds. First, brain entropy could serve as a translational biomarker to identify responders early in the treatment course, potentially reducing trial costs and improving patient stratification. Second, regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) increasingly require mechanistic data to support new drug applications for psychiatric indications. The demonstration of a quantifiable, brain-based mechanism may facilitate regulatory review and post-marketing surveillance.

For research policy, the results highlight the value of integrating neuroimaging endpoints into clinical trials of psychedelic and dissociative therapies. Funding agencies and institutional review boards may prioritize studies that combine clinical and mechanistic outcomes, accelerating biomarker validation. However, the use of entropy as a surrogate endpoint remains investigational and requires further replication in larger, diverse populations.

Risks, Limitations, and Unknowns

Despite promising results, several risks and limitations warrant caution. The trials were relatively small (sample sizes not disclosed in the summary) and may be underpowered to detect rare adverse events or subtle subgroup effects. Brain entropy is a complex, multivariate measure that can be influenced by technical factors such as scanner variability, preprocessing pipelines, and participant movement. There is also uncertainty regarding the specificity of entropy changes to ketamine versus other rapid-acting antidepressants or non-pharmacological interventions.

From a clinical perspective, the relationship between acute entropy changes and long-term remission remains unproven. There is a risk that over-reliance on neuroimaging biomarkers could divert attention from patient-reported outcomes and real-world functioning. Furthermore, the dissociative and psychotomimetic effects of ketamine, even at low doses, carry safety and abuse liability concerns that are not addressed by entropy measures alone.

Outlook: Toward Mechanism-Based Psychiatry

The demonstration that low-dose ketamine modulates brain entropy in TRD patients marks a step forward in understanding the neurobiological basis of rapid antidepressant action. As the field moves toward mechanism-based psychiatry, objective biomarkers like brain entropy could improve trial efficiency, regulatory clarity, and personalized treatment strategies. Future research should focus on validating entropy as a predictive and monitoring tool across diverse patient populations, dosing regimens, and therapeutic modalities.

For now, brain entropy remains an experimental biomarker, but its integration into clinical trial design may set a precedent for the next generation of psychedelic and dissociative drug development. Stakeholders should balance enthusiasm for mechanistic innovation with rigorous attention to safety, replicability, and patient-centered outcomes.

By Dr. Jamie L. Carter, PhD (Neuroscience). Reviewed by Dr. Priya Menon, MD, October 27, 2026. We base our analysis on the original peer-reviewed article and primary neuroimaging trial data as cited above.